Quick Answer
AN2 Therapeutics, Inc. reported Total Assets of $61.95 million for fiscal year 2025.
AN2 Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $61.95M | -32.7% |
| 2024 | $92.09M | -33.6% |
| 2023 | $138.74M | +35.3% |
| 2022 | $102.56M | +57.0% |
| 2021 | $65.32M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $67.23M | -31.2% | -11.3% |
| June 30, 2025 | $75.83M | -30.1% | -6.8% |
| March 31, 2025 | $81.34M | -32.9% | -11.7% |
| December 31, 2024 | $92.09M | -33.6% | -5.7% |
| September 30, 2024 | $97.69M | -36.5% | -9.9% |
| June 30, 2024 | $108.48M | +9.7% | -10.5% |
| March 31, 2024 | $121.26M | +33.1% | -12.6% |
| December 31, 2023 | $138.74M | +35.3% | -9.8% |
- AN2 Therapeutics, Inc. showed a decrease of -32.7% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, AN2 Therapeutics, Inc.’s total assets has declined by 5.2% (from $65.32 million to $61.95 million).
- The most recent figure is from AN2 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: